IBEX Guides to $700-$715 Million After Record FY2026

IBEX Ltd closed fiscal 2026 with record revenue of $644.1 million and guided fiscal 2027 revenue to $700-$715 million, citing Health Tech demand and AI agent deployments.

IBEX Ltd (IBEX) finished fiscal 2026 with record revenue of $644.1 million and told investors to expect between $700 million and $715 million in fiscal 2027, a guidance range the company tied to strength in its Health Tech vertical and to the rollout of AI agents across client programs.

For a business that sells outsourced customer experience — call centers, chat support, back-office handling, all of it performed on behalf of someone else's brand — that combination is the whole story of the current cycle. Revenue is still expanding, but the unit being sold is quietly changing from a seat and a headset to a mix of software and supervised human escalation.

What the guidance range actually implies

Work the arithmetic on the two supplied numbers and the shape of the year becomes clearer. Going from $644.1 million to the low end of guidance implies growth of roughly 8.7%; the high end implies roughly 11.0%. The midpoint of the range sits at about $707.5 million, which would be an increase of roughly $63.4 million on the year. Those figures are illustrative calculations from the two revenue numbers the company disclosed, not separately reported metrics.

A spread of $15 million between the floor and the ceiling is not especially wide for a company of this size, which tends to signal that a good share of the year is already contracted rather than dependent on new logos landing on schedule. The guidance was delivered alongside the fourth-quarter results, as reported by GuruFocus.

Double-digit-adjacent growth is a respectable outcome in outsourced CX, a sector where pricing pressure is chronic and where clients renegotiate rates at every renewal. The question investors will press on is not whether the top line grows — the guidance answers that — but what mix of volume, price and automation gets it there.

Why the Health Tech line matters more than its size

IBEX singled out Health Tech as a growth driver. Healthcare-adjacent customer support is one of the harder corners of the industry to serve: it carries regulatory obligations around patient data, it demands trained agents rather than interchangeable ones, and enrollment cycles create sharp seasonal peaks that a provider has to staff for. All of that raises the barrier to entry, and barriers to entry are what allow a CX vendor to hold price.

That is the strategic logic behind the vertical. Generic retail or telecom support is the most commoditized end of the market and the most exposed to being replaced outright by a chatbot. Regulated, complex, consequence-heavy interactions are the ones where a human stays in the loop longest — and where the client is least willing to switch providers over a few cents of hourly rate.

If Health Tech is carrying an outsized share of the incremental revenue implied by fiscal 2027 guidance, the mix effect on margins should be favorable even before any automation benefit lands.

AI agents cut both ways on the income statement

The second driver IBEX named — AI agent deployments — is the one the whole sector is being repriced around. An AI agent that resolves a routine query end to end removes a chargeable human interaction. If the contract is priced per minute or per seat, that is revenue walking out the door. If it is priced per resolved outcome, the vendor keeps the fee and drops the labor cost, and gross margin expands.

The second driver IBEX named — AI agent deployments — is the one the whole sector is being repriced around.

Which of those two worlds a CX provider lives in is the single most important thing to understand about its next three years. The bear case for the industry is straightforward: automation deflates volumes faster than new work replaces them, and the outsourcers end up shrinking a business they built on headcount. The bull case is that automation handles the cheap, low-margin tier while providers keep the complex tier and capture software-like economics on the layer they built themselves.

IBEX guiding to growth of roughly 8.7% to 11.0% while talking up AI deployments is, on its face, an argument for the second version. Deflation is not showing up in the top line yet. Whether it shows up in the margin line, favorably or otherwise, is what the next four quarters will settle.

Where the shares stand

IBEX last traded at 37.26, up 0.59% on the day, with a session range of 36.81 to 37.83 against a prior close of 37.04, as of the market close on Sept. 10, 2026. The move came on a broadly weak tape: the S&P 500 tracker closed at $757.83, down 0.60%, the Nasdaq 100 proxy at $708.69, down 1.06%, and the Dow tracker at $520.75, down 0.63%.

Holding a small gain while all three major benchmarks sold off is a modest but real relative-strength signal, and one worth noting in a week when anything touching AI has been trading on sentiment rather than fundamentals. A single session proves little on its own, but small-cap services names typically amplify broad market moves rather than resist them.

The metrics that decide whether this works

Revenue guidance is the headline. It is not the number that determines whether the AI thesis is paying off. A few things to track through fiscal 2027:

Revenue per employee. If automation is genuinely doing work, this figure should climb faster than the top line. Growth in revenue with a flat or falling headcount is the clearest evidence of operating leverage.
Gross margin direction. Automation that expands margin is a business model change. Automation that leaves margin flat is a price concession passed straight to the client.
Contract structure. Any shift disclosed from per-seat or per-minute pricing toward outcome-based pricing is the structural tell.
Health Tech concentration. Growth in a specialized vertical is valuable until a single large client accounts for too much of it. Diversification within the vertical matters.
The low end of the range. Landing near $700 million rather than $715 million would suggest volume deflation is offsetting new wins — the scenario the sector fears.

What IBEX has delivered is a record year and a forecast for another one, with the composition of that growth as the open question. In outsourced customer experience right now, composition is arguably the only question that matters. The providers that emerge intact will be the ones that sold clients an outcome rather than an hour, and fiscal 2027 is when the difference starts showing up in the numbers.

Key facts

FY2026 revenue: $644.1 million, a company record
FY2027 guidance: $700 million to $715 million
Named growth drivers: Health Tech vertical and AI agent deployments
IBEX last close: 37.26, +0.59%, as of Sept. 10, 2026, 20:00 GMT

Frequently asked questions

How much revenue did IBEX report for fiscal 2026?

IBEX Ltd closed fiscal 2026 with revenue of $644.1 million, which the company described as a record. The figure was disclosed alongside its fourth-quarter fiscal 2026 results. Management attributed the year's performance in part to strength in its Health Tech vertical and to the deployment of AI agents across client programs.

What is IBEX guiding to for fiscal 2027?

The company issued fiscal 2027 revenue guidance of $700 million to $715 million. Measured against fiscal 2026 revenue of $644.1 million, that implies growth of roughly 8.7% at the low end and roughly 11.0% at the high end — an illustrative calculation from the two disclosed revenue figures rather than a separately reported metric.

What does IBEX actually do?

IBEX operates in outsourced customer experience, commonly called CX. It handles customer support, chat, voice and back-office work on behalf of other companies' brands, rather than selling to consumers directly. Revenue is traditionally earned per agent seat or per minute of interaction, though the industry is shifting toward outcome-based pricing models.

Why do AI agents create risk as well as opportunity for CX firms?

An AI agent that resolves a customer query removes a billable human interaction. Under per-seat or per-minute contracts, that reduces revenue. Under outcome-based contracts, the provider keeps the fee while cutting labor cost, which expands margin. The contract structure therefore determines whether automation is a threat or a profit driver for the vendor.

How did IBEX shares perform at the most recent close?

IBEX last traded at 37.26, up 0.59% from a prior close of 37.04, with a session range of 36.81 to 37.83, as of Sept. 10, 2026. That gain came on a down day for the broad market, with the S&P 500 tracker off 0.60%, the Nasdaq 100 proxy off 1.06% and the Dow tracker off 0.63%.

What should investors watch in fiscal 2027?

Revenue per employee is the clearest test of whether automation is producing real operating leverage, since rising revenue on flat headcount indicates genuine efficiency. Gross margin direction, any disclosed shift toward outcome-based contract pricing, and concentration risk within the Health Tech vertical are the other key indicators through the year.

Sources

IBEX Ltd (IBEX) (Q4 2026) Earnings Call Highlights: Record Revenue and AI-Driven Growth Momentum — GuruFocus

Photo: Yan Krukau · Pexels Licence — source